Category Archives: Animal Rights News

Big Questions, but few answers from opponents of animal research

A recent edition of the BBC1 Program called “The Big Questions” offered a brief debate on animal research. Among those discussing the issues was SR’s founder, Tom Holder. Within this post we will discuss some of the many issues which were touched upon, but barely explored in this brief debate.

Some of the questions centered on moral issues, other on scientific ones. At the beginning of the discussion Prof. John Stein of Oxford University explained his use of monkeys in studying Parkinson’s disease, after which he was asked if he would experiment on great apes.  He replied he would not, unless there was some extreme circumstance that required them.

Where would you draw the line?” — countered the host.

Let us pause for a second here. This is an important question that is worth asking. But first let us consider – and reject all the theories that do not involve drawing any lines at all.  What theories are these?

One is the Cartesian view, which posits animals do not truly suffer, do not really have emotions, and do not really have interests of their own. Consequently, the Cartesian view is that humans can use animals as we please. We do not know any living scientist or philosopher that would seriously defend this view.

The other theory that does not draw any lines is the animal rights view, in which all living beings have the same basic rights to freedom and life as a normal human. Although most members of the public reject this view as making no sense at all, nobody in the panel cared to explain, nor did the host bother to ask, what justifies this stance.

What Prof. Stein articulated as a justification was a version of something called the sliding scale model.  Here, the moral weight of a living being’s interests depends on the individual’s degree of cognitive, affective and social complexity. Where we draw the line for different types of experiments in animals is a valid and important question, but we can only ask it that if we all agree with the notion of graded moral status.

Opponents of research reject such a theory.  Alistair Currie, from PeTA, stated:

Suffering is suffering.  We have a moral obligation not to impose it on anybody.”

We generally agree that unnecessary suffering should not be imposed on other living beings, and as Prof. Stein stressed, scientists work hard to ensure that suffering is eliminated or reduced to an absolute minimum in laboratory animals. We do not think there are absolute moral principles.  Even “thou shall not kill” permits exceptions, such as in the case of self defense. Another example is the infliction of harm to other human beings that was, for most of us, morally justified and necessary when it came to liberating the concentration camps in Nazi Germany.

If we truly had an absolute moral obligation to never impose suffering on anybody, as PeTA representative Currie suggests, liberating concentrations camps would be morally wrong. We might accept such a declaration from someone who is a declared pacifist, but we have plenty of evidence to suggest that PeTA is a far from being such an organization.  PeTA remains morally confused.

Invariably, when opponents of animal research fail to make an ethical case for their position, they attack the science. In this case, it was Kailah Eglington, representing the Dr Hadwen Trust, who was in charge of this strategy.

“Scientifically looking at the facts, the animal model is flawed.” — she declared without even blinking.

Wait a second. Where was she when Prof. Stein explained how he found an area of the brain that when inactivated could relieve the symptoms of Parkinson’s? How does she explain his success?  Or does she deny the benefits of the work?

Ms. Eglington also suggested that Prof. Stein could have used non-invasive methods in humans, such as MEG, suggesting the same information could be obtained by this techniques. As Prof. Stein pointed out in his response this is flatly wrong. Prof. Stein not only uses a range of such techniques, including MEG and fMRI alongside his studies in macaques, but with his colleagues at Oxford University pioneered the use of MEG as a research method in patients undergoing deep brain stimulation. However, none of the non-invasive methods can yield the same data that one obtains using micro-electrode recordings from the brain, as we discussed in an earlier post on the limitations of fMRI.

A quick visit to the Dr. Hawden Trust web-site reveals that they state with absolute certainty that:

Alternatives to animal experimentation are available in virtually every field of medical research.”

Wow…   Let’s be clear: this is complete utter nonsense that deserves to be filed here. Should we be surprised at the lack of sensible science by someone who, on the side, founded an organization which claims that “the power of positive thinking” can treat physically debilitating conditions.

Kailah Eglington furthered her pseudo-scientific nonsense by claiming that: “9 out of 10 drugs that are tested on animals successfully fail in humans“. The problem here is the mistaken blame on the animal model – these same drugs have already passed pre-clinical non-animal tests such as cell cultures and computer models; moreover, about 90% of drugs fail at every stage of development – meaning that 90% of those that pass early clinical trials in humans still fail to make it to market – this is not something we can blame the animal model for. We have previously written a full and clear rebuttal of the 90% claim – however it continues to be used by the animal rights community.

Such examples go to show a common problem for advocates of science – that it takes a lot longer to debunk junk science, than it does to make it up. While Tom Holder and Prof. Stein argued science’s case very well the debate highlighted some of the limitations of this format, though perhaps this is all we can expect from a format that tries to address Big Questions in 15 min of television programming.  It seems the goal here is more to get opposing sides to have a screaming contest rather than to provide an opportunity for thoughtful exploration of the questions at hand.

Speaking of Research

Professor Doudet vindicated as investigation rejects animal rights allegations.

Two weeks ago we discussed the targeting by Canadian animal rights group Stop UBC Animal Research (STOP) of University of British Columbia scientist Professor Doris Doudet. STOP alleged that Prof. Doudet had performed experiments on monkeys without the approval of the UBC Animal Care Committee, and then lied in a scientific paper to cover her tracks, though as we reported at the time their allegations of professional misconduct against her were based on a deliberate misrepresentation of the facts. We are now happy – though in the circumstances not very surprised – to learn that an independent investigation of Prof. Doudet’s work has dismissed the allegations made against her.

According to today’s report in the Vancouver Sun, the Canadian Council on Animal Care (CCAC) carried out a detailed review of the research undertaken by Prof. Doudet’s team, and found:

no evidence to support allegations of animal cruelty against a University of British Columbia research team related to the deaths of four macaque monkeys.”

An earlier report on CTV news adds that the CCAC investigation:

found no evidence to support allegations that UBC was subjecting monkeys to cruel research experiments that were not overseen by the UBC Animal Care Committee.”

The letter from the CCAC to STOP detailing the conclusions of their investigation can be read here.

We asked Prof Doudet her views about this week’s developments, welcoming the news she said:

It is distressing to be wrongly accused, but the truth prevailed and we are all grateful for it.  MPTP always had unexpected effects, not only in monkeys but in the humans who unknowingly injected themselves with it: Out of the more than 100 people who were exposed to the drug in the early 80s, only a handful developed severe parkinsonism and there is no way to predict who will have such a severe negative response. But the MPTP primate model and the knowledge gained from it have played an important part in the basic understanding of physiological mechanisms involved in the disease, and this has been key to the development of many therapies for Parkinson’s disease, including DBS and the current testing of many gene therapies.”

We too welcome this news, though we wonder whether a formal investigation was really required to confirm what had been patently obvious right from the start.

Speaking of Research

The 21st Century Scientist

Earlier today we discussed some of the characteristics of the animal rights crank, so it’s perhaps appropriate that an award announced earlier this week has highlighted the best qualities of the scientists who are really shaping 21st century medicine.

The Grete Lundbeck European Brain Research Foundation has awarded its 2nd €1-million Brain Prize to Professor Karen Steel of Cambridge University, founder of the Mouse Genetics Programme at the Wellcome Trust Sanger Institute, and Professor Christine Petit of the College de France, head of the Genetics and Physiology of Hearing laboratory at the Institut Pasteur in Paris, for:

their unique, world-leading contributions to our understanding of the genetic regulation of the development and functioning of the ear, and for elucidating the causes of many of the hundreds of inherited forms of deafness”

Continue reading

A Brief History of Deep Brain Stimulation

An on-going campaign against the use non-human primates to study Parkinson’s disease (PD) at the University of British Columbia prompted me to summarize some basic facts about the work and the history of a successful therapy was developed.

Why is the work done?

In the U.S. alone there are between 500,000 and 1 million people living with PD, with about 50 to 60 thousand new diagnoses every year.  The National Institutes of Neurological Disorders and Stroke (NINDS) estimates the cost to our society is at least $5.6 billion, including both direct medical expenses and indirect costs from lost income, disability payments and so on.  Moreover, the emotional toll of Parkinson’s on patients and families is enormous.

One of the most successful therapies developed for PD  involves the electrical stimulation of deep structures within the human brain — so called deep brain stimulation (DBS).  The technique works remarkably well for some patients.

How was the method developed?

Back in 1983 Langston and colleagues reported on a clinical case study of four patients that developed Parkinsonism after illicit drug use.  Analyses of the drugs they had taken via mass spectroscopy revealed primarily MPTP, but there were also traces of MPPP. They suggested MPTP might be the most likely culprit and suggested that:

“Given the pathologically studied case, the relative purity of the clinical syndrome seen in our patients, and its remarkable clinical resemblance to Parkinson’s disease, the drug [MPTP] may be of value in producing an animal model of Parkinson’s disease.”

In other words, a group of clinicians studied a handful of human patient cases, identified a potential link between MPTP toxicity and the development of PD, and proposed to follow up with animals studies.

In 1983, Burns and colleagues follow up on this idea by trying to replicate the disease in monkeys.  Indeed, intravenous administration of MPTP caused the animals to develop rigidity, postural tremor, eyelid closure, and many other symptoms of Parkinsonism.  Moreover, their symptoms could be relieved by the administration of L-dopa, exactly as it was the case with the Langston et al patients. The animal model also allowed them to characterize the selective destruction of dopaminergic neurons in the subtantia nigra and a marked reduction in the dopamine content of the striatum.  They offered MPTP treated monkeys as a model to explore therapies for PD.  How many animals were used?  Twelve.

Although these anatomical studies shed light into the brain areas that might be involved in PD it was unclear what functionally was causing the observed symptoms.  Subsequent work by Mitchell et al (1989) using single unit recordings and lesion studies in monkeys pointed to increased activity in the subthalamic nucleus (STN) as generating motor abnormalities.  How many monkeys were used?  Eight.

A natural question arose from these studies.  Would suppressing the activity of these hyperactive neurons help in alleviating the symptoms of the disease?

Two studies showed that lesions of the STN could reverse the effect of Parkinson symptoms in the monkey MPTP model, with studies by Bergman et al (1990) and Aziz et al (1991).  These studies not only began to dissect the functional connectivity within the basal ganglia-thalamocortical circuit, but also offered evidence that inactivation of the STN could work as a potential therapy for Parkinson’s.   How many monkeys were used in these two studies?  Four.

Shortly after, Benazzouz et al (1993) showed that instead of lessoning the STN one could use high frequency stimulation of the STN to alleviate the symptoms in MPTP treated monkeys.  Supposedly, the high frequency stimulation suppresses the activity of these cells acting as a “virtual lesion”.  How many monkeys were used here?  Two.

Indeed, Limousin et al (1995) successfully applied this method in three patients and concluded:

“In this study, bilateral subthalamic nucleus stimulation improved akinesia and rigidity in three patients with Parkinson’s disease.  This is in agreement with the results obtained in monkeys with MPTP-induced parkinsonism by lesions or stimulation of the sub-thalamic nucleus.”

Number of humans used?  Three.

And to dispel any remaining doubts he writes in a recent review that:

“The knowledge of the functional changes of basal ganglia activity in the parkinsonian state as it emerged from extensive experimental studies on animal models has provided the theoretical basis for surgical therapy in PD. The 6-hydroxydopamine (6-ODHA) rat model and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of PD provided powerful research tools for uncovering the pathophysiology of changes in functional basal ganglia activity in PD.” 

And finally one may ask, ho many human patients have benefited from this type of work?

The answer is 80,000 and counting.

What do these patients think of such studies?

Here is one — please listen to him carefully.

And if you truly want to learn more here are some extra resources:

SfN brain briefing on PD discoveries.
The Michael J. Fox Foundation
Information from National Institutes of Neurological Disorders and Stroke.
Information from Understanding Animal Research.

STOP lying about research at the University of British Columbia

In a post a couple of weeks ago entitled “End of primate research at the University of Toronto?” Allyson Bennet wrote about the truth behind the spin that primate research has ceased at the University of Toronto (UT), commenting that:

 If nothing else, those inclined to dodge should consider that they are deriving benefit from the work of their colleagues at the institutions still willing to assume the risk and responsibility.”

It hasn’t taken very long for other animal rights groups in Canada to pick up on UT’s perceived change of policy, with a Vancouver-based group named STOP UBC Animal Research (STOP) quick to demand that the University of British Columbia (UBC) follow UT’s example.

For more than a year now STOP have been engaged in a high-profile campaign against animal research at UBC, prompting UPC to respond by providing information about the animal research they undertake. One of their main targets has been Professor Doris Doudet, who employs advanced imaging modalities such as positron emission tomography (PET) for the evaluation of functional, neurochemical, and anatomical changes in the brains of animal models of Parkinson’s disease.

In a paper published online last November in the Journal of Cerebral Blood Flow and Metabolism Professor Doudet and her colleagues reported that they had used PET to confirm that abnormal metabolic patterns recently observed in the brains of Parkinson’s disease patients are also found in the brains of monkeys which have been treated with the drug MPTP to kill the dopamine producing neurons in the brain and induce Parkinsonism. This result both confirmed the close similarity between MPTP-induced Parkinsonism and Parkinson’s disease, and provides another useful way in which the effects of candidate therapies for the treatment of Parkinson’s disease can be evaluated in this much-used animal model of Parkinson’s disease.

Unfortunately in the course of the experiment four of the eleven monkeys treated with MPTP developed an unusually severe response, and rather than recovering after the experiment – as is usually the case with monkeys treated with MPTP – they had to be euthanized. The Journal of Cerebral Blood Flow and metabolism paper makes it clear that Prof. Doudet and her team responded quickly and correctly to the unexpected situation to minimize any suffering the animal’s experienced.

Not surprisingly STOP are seeking to make capital out of this event…but this is where animal rights propaganda parts company with the facts.

In a statement to the UBC student newspaper Ubyssey STOP claim that far from being accidental the four monkey deaths were planned:

a 2010 progress report on Doudet’s study indicated four monkeys were to be “sacrificed to neuropathology”—two at the six-month mark after showing mild symptoms of Parkinson’s, and the final two after twelve months.

“Animals should be able to recover from the Parkinsonism that researchers inflict on them,” Birthistle said. “She’s intending to kill them all along, and then they’re talking about it as being unforeseen circumstances.””

So what is this “2010 progress report? Well, another statement by STOP quoted in a Vancouver newspaper explains that they are referring to a study named “L91”.

So what is L91 all about?

It’s not the first time that STOP have complained about study L91, back in January of last year they staged a protest against it. L91 is a project planned by Prof. Doudet to use PET to study the effect of injection of the proteasome-inhibitor Lactacystin on the brain function of four macaques, and a description of the proposed project can be found on page 25 of this TRIUMF publication. Lactacystin injection is a relatively new animal model of Parkinson’s disease, recreating the damage to the proteasomes of the dopamine secreting neurons of the substantia nigra region of the brain observed in Parkinson’s disease patients, and has the potential to become a valuable resource for evaluation new therapies.

So it’s abundantly clear that the proposed study L91 is NOT the same as the study published last November in the The Journal of Cerebral Blood Flow and Metabolism, as the former plans to use lactacystin to induce Parkinsonism while the latter used MPTP. It is equally clear that STOP are well aware that these are not the same study, as they have access to all the relevant documents.

Yet, not only to STOP repeatedly and dishonestly claim that these are the same study, but on the basis of this claim they go on to make false allegations of professional misconduct against Prof. Doudet and demand that UBC suspend her from her duties and carry out a full investigation.

And I’ll bet that they will express surprise and outrage when UBC refuses to comply with their demands!

Before leaving this subject it’s worth addressing the importance of the role of animal research in Parkinson’s disease research, something that we are well aware of thanks to Pro-Test’s own Prof. Tipu Aziz, whose research using the MPTP model of Parkinsonism made major contributions to making deep brain stimulation (DBS) for Parkinson’s disease the success it is today.  I’ll value the views of the neuroscience community as a whole – including great neuroscientists such as the physician-scientist Prof. Alim-Louis Benabid, pioneer of DBS for Parkinson’s disease – over those of the few fringe scientists that STOP can scrape together.  Prof. Benabid and other genuine experts on Parkinson’s disease recognize that while Parkinsonism models such as the MPTP monkey do not recreate every aspect of Parkinson’s disease they play a vital role alongside clinical research in uncovering the process that cause the disease and its symptoms, and in the development of new therapies for Parkinson’s disease.

As Prof. Benabid wrote in a review in 2004:

The knowledge of the functional changes of basal ganglia activity in the parkinsonian state as it emerged from extensive experimental studies on animal models has provided the theoretical basis for surgical therapy in PD. The 6-hydroxydopamine (6-ODHA) rat model and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of PD provided powerful research tools for uncovering the pathophysiology of changes in functional basal ganglia activity in PD. “

and in a review published this year

The specific effect of DBS at high frequency, discovered during a VIM thalamotomy, was extended to the older targets of ablative neurosurgery such as the pallidum, for tremor in Parkinson’s disease (PD), dyskinesias, essential tremor, as well as the internal capsule to treat psychiatric disorders (OCD). A second wave of targets came from basic research (in this instance animal research –PB), enabled by the low morbidity, reversibility, and adaptability of DBS. This was the case for the subthalamic nucleus (STN) which improves the triad of dopaminergic symptoms, and the pedunculopontine nucleus (PPN) for gait disorders in PD. “

As with so many areas on medicine it is the confluence of animal and clinical researhc that is driving advances in the treatment of Parkinson’s disease.

Rather ironically animal rights organizations like STOP and their supporters are very quick to claim that Prof. Benabid’s serendipitous discovery that electrical stimulation of the ventralis intermedius could reduce the tremor associated with Parkinson’s disease demonstrates that research using the MPTP model is unnecessary. They seek to co-opt his stature as a leading neuroscientist while simultaneously ignoring the fact that he not only recognizes the importance of animal models of Parkinson’s disease but himself undertakes studies with the MPTP Monkey model and other animal models of Parkinson’s disease.

So, the question is who you are going to believe, leading neuroscientists like Prof. Doudet and Prof. Benabid, or STOP? Somehow I doubt it will take you long to come to a decision!

Paul Browne

Part 2: University of Toronto ends live primate research – Outsourcing Controversy

 Earlier this week we wrote about the University of Toronto’s public statements concerning the end of their on-site primate research. A number of broader questions were raised by considering similar cases and articles.  Among them, what does it mean for a university to claim that it does not engage in a particular type of research?  In the case of the University of Toronto, the same article announcing the end of their primate research indicated that Univesity of Toronto researchers will continue primate studies at other institutions. 

Although this seems like a small point that concerns only a single animal research program, it is illustrative of larger questions and issues that deserve more thoughtful consideration.  One is what it means to say that a researcher, institution, or nation does or does not conduct a particular type of research. It is not at all obvious, and thus is an easy thing to manipulate in public presentation. For example, ask the following questions:

  1. Does that mean only that they do not house animals and conduct studies, or do not conduct that work independently on their own campus or within their own borders?
  2. Or does it mean that they not only do not conduct the work, but also do not support the work in any way, with collaborative effort, resources, or their approval? 
  3. Or does it mean that they not only do not conduct the work, but also do not support the work and would refuse any benefit arising from the work?

It is not only the University of Toronto ending its housing of monkeys and instead relying on collaborative opportunities in the U.S.that raises these questions. The point is also well illustrated in considering whether Canada and other countries are, or are not, involved in biomedical research with chimpanzees. One of the frequently raised points used to argue against ape research is that biomedical research with chimpanzees is conducted in only two countries — the U.S. and Gabon.  But what does that mean? And is that really true?

In fact, a recent CTV news show highlighted the fact that studies for Canadians are performed at a U.S. chimpanzee research facility funded largely by a federal grant to maintain national research resources in the U.S.  The fact that Canadians are involved in chimpanzee research is not hidden in any way, but is easy to misconstrue.

In Canada, there’s no outright ban, but no one is actually doing it.

Instead, Canadians commission studies at research facilities like the New Iberia Research Center in Louisiana, the largest facility of its type in the world. It’s home to nearly 7,000 primates, 360 of them chimpanzees.”

It is not only Canadians. Scientists from a number of other countries engage in behavioral and biomedical research collaboration involving chimpanzees housed in U.S. research institutions. Furthermore, when the Netherlands became the last European country to ban chimpanzee research almost a decade ago, it was acknowledged that because the opportunity for chimpanzee research remained in the U.S.everyone could be assured of continuation of the work without the cost, controversy, or responsibility of having to maintain the possibility within their own country.  A 2003 article highlights this point:

The end of European ape research, long sought by animal rights activists, was accelerated by a report published in 2001 by the Royal Netherlands Academy of Sciences (KNAW). It concluded that high costs and decreasing scientific need had made chimp studies all but superfluous. In rare instances where ape research will be crucial to combat a human disease, the panel said, large colonies funded by the National Institutes of Health (NIH) in the U.S. would be better equipped.

However, even in parliament itself some hypocrisy was acknowledged. Because ‘if the occasion arises’, the government quoted the KNAW report, Dutch researchers would still be free to do experiments abroad. Observed House member Bas van der Vlies (SGP): ‘Since through a back door [the Netherlands will profit from [ape research elsewhere, I see no reason for us to start beating our chests like gorillas.’”

The point made by Bas van der Vlies is a good one and one especially relevant now as the U.S. weighs legislation to end invasive chimpanzee research.  It is also more broadly relevant because it underscores why the decision of single entity, institution or nation, to end a particular type of research must be viewed within the context of the range of alternative opportunities and avenues that will serve the overall goal.  In other words, the decision to ban an avenue of research means one thing if that choice will result in a true end to the work. The same decision is inherently less risky if it is cushioned by knowledge that another institution or another country is committed to maintaining that research avenue and shouldering the accompanying burdens.

It is also true that the decision to “end” a particular kind of work is often more reflective of different types of cost considerations.  For example, note increasing outsourcing of animal research to other countries with less developed regulatory structure and lower costs. Whether that is good for animal welfare, science, research institutions, and the public is a topic of discussion among scientists and is one that should be given more thoughtful public consideration. We believe the US public is better served by advocating for reasonable improvements in animal welfare while keeping important medical research at home. The adoption of unrealistic policies and regulations that dramatically increase the cost of the work, while not significantly impacting on the well-being of the animals, will help drive the research overseas, with negative consequences on the biomedical leadership of our country and uncertain consequences for the well-being of the animals.  

So how do we tell the difference between individuals, institutions, and countries genuinely committed on moral or ethical grounds to ending particular types of research, rather than in only displacing it to others?  One piece of evidence would be for those claiming that the work is either unnecessary or unethical to also make clear that they do not simply outsource the work to other institutions or countries. 

Another would be for them to decline any benefits from the work.  For example, although we are aware of no efforts underway to preclude citizens of countries that disallowed such work to benefit from the findings or any advances made through chimpanzee biomedical research, for example hepatitis C vaccines currently under development, it would seem that this would be an easy way for people to affirm their commitment to the global picture. (Whether it should be habitat countries or a world-wide body who provides consent on behalf of the wild apes for whom conservationists are arguing should benefit from vaccines developed from research in laboratory studies of nonhuman primates might be a separate issue.)

What is gained from considering this more complicated picture?  In the case of the recent University of Toronto press coverage, a reminder that it is disingenuous at best to solicit public approval by disavowing research that the institution has conducted, has benefited from, and will continue to be involved in — albeit with the majority of risk and cost assumed by other institutions. In the case of chimpanzee research, a reminder that as long as non-U.S. interests benefit from and participate in studies conducted in the U.S., it is not accurate to claim that it is only the U.S.that sanctioned and benefited from such work.  And that includes the apes in Africa who could benefit from the vaccines developed via laboratory research in theU.S. and elsewhere.

Finally, we would advise a critical eye towards any articles in which universities, pharmaceutical companies, or countries claim that they are not engaged in primate or other animal research.  Those who have simply chosen to do the same work elsewhere or via collaboration should be clear about their involvement. Similarly, those whose work depends on data, tissues, or animal models developed by others, or at other institutions, should acknowledge a responsibility and involvement in the live animal work as well. 

Allyson J. Bennett

A welcome end to random-source dog and cat dealers

The National Institutes of Health has announced that starting October 1, 2012, NIH funds may no longer be used to buy cats from Class B dealers. A similar prohibition in the purchase of dogs from Class B dealers takes effect in 2015.

Although dogs and cats constitute only small percentage of research animals, they have been used in American biomedical research for over a century for studies of cardiovascular and neurological diseases, and for other areas of research including recent studies that led to a gene therapy for the eye disease Leber’s congenital amaurosis, whose success was reported widely last week.  The use of these animals is tightly regulated by the Animal Welfare Act, and they are only employed for studies where lower species do not provide adequate models.

Class B dealers are individuals licensed by the USDA under the Animal Welfare Act to resell animals they did not breed themselves. Class A dealers are breeders who do raise the animals themselves. Class B dealers may purchase dogs and cats from sources such as municipal pounds, from individuals who bred and raised the animals, and from other licensed dealers. They are required to keep records on where they got each animal and to hold pound animals for a minimum period so that if an unwanted animal was actually a stray, the owner has time to reclaim it.

Animal statistics in 2010 (US data) - Dogs account of 0.25% and cats 0.08% of the total number of animals used.

Class B dealers used to provide a large number of cats and dogs for research because they were virtually the only source for older animals and for some breeds. Regrettably, some Class B dealers used practices that violated the Animal Welfare Act both in terms of how they acquired animals and how they treated them.  The National Academies of Science studied the specific areas of science where Class B dogs and cats were being used and concluded that NIH could develop alternate supply mechanisms to replace them. NIH decided the best way to facilitate the transition was to provide an initial outlay of funds so that Class A dealers could begin raising older dogs of the breeds required for scientific research. It is expected that these breeders will be able to produce the necessary animals by 2015.

After October 1, 2012, NIH-grant supported research can only use cats from the following sources: Class A dealers, privately owned research colonies, or client owned animals, such as animals that participate in veterinary clinical trials.  The same policy will apply to dogs in 2015 when the Class A breeding program is in full swing.

The transition of NIH-funded research away from the use of Class B dogs and cats is an example of how measures can be taken to correct ethical problems regarding the treatment of animals.  When ethical concerns exist, thoughtful and deliberate steps can address those concerns, while preserving important biomedical research projects.

Bill Yates and Alice Ra’anan.

Bill Yates is the Chair of American Physiological Society Animal Care and Experimentation Committee. Alice Ra’anan is Director of Science Policy for the American Physiological Society. The views expressed above are exclusively those of Bill Yates and Alice Ra’anan and do not necessarily represent those of their employers.

Animal rights campaigns: When free speech takes a hideous turn

An important principle of American democracy is that the free exchange of ideas is crucial to social progress. We accept that protected speech can be often be ugly, provoke social unrest and include acts of civil disobedience. Yet, as far as possible, we must ensure that people are free to express their ideas - this cannot happen when individuals on one side of the debate are harassed and threatened. We’ve seen this happen in the abortion debate. Now, we see it unfold in the animal rights debate.

Organized harassment, intimidation, threats and firebombs directed at individuals involved in biomedical research involving animals, as well as other animal-related industries, and their families, are neither uncommon, nor are they protected forms of free speech.  While these are the tactics are used by a relatively small group of animal rights extremists who work under the motto – “animal liberation by all means necessary”, the escalation of violence from radical elements of the movement has been fueled in recent years by a larger group of activists who sit by the sidelines celebrating these criminal acts and inciting individuals to more violence. There is an even larger majority which appears at least to silently approve.  Only a disappointingly tiny group of animal rights philosophers and organizations have been vocal in condemning the violence from the fringes of the animal rights movement.

Some of the activists have taken to the internet in order to publish the addresses of their “targets” along with carefully worded incitements to violence; others have initiated campaigns of hate against their victims; yet others have shown up outside the targets’ front doors at night, wearing ski-masks, and frightening children inside with chants like “we know where you sleep”. This is, in good part, the free speech so many activists want to defend.

Protesters scream outside a researcher's home, routinely harassing the entire neighborhood

The behavior of animal rights extremists parallels that of radical, anti-abortion groups that targeted physicians who provided abortions to women who needed or requested them.  To seek a remedy to the escalating violence from these groups, President Bill Clinton passed the Freedom of Access to Clinic Entrances Act, that prohibits trespassing, vandalism, threats of violence, stalking, arson and bombings directed at reproductive health care clinics or their personnel.  The Animal Enterprise Terrorism Act simply attempts to control the criminal acts of animal rights extremists in a similar fashion.

The Animal Enterprise Terrorism Act (AETA) contains a clause indicating that nothing within it should be construed to “prohibit any expressive conduct (including peaceful picketing or other peaceful demonstration) protected from legal prohibition by the First Amendment to the Constitution.”  It is clear that only illegal conduct that is not covered under the First Amendment can be construed as violating the Act. Animal activists and advocates willing to express their views and educate the public regarding them can do so freely.

It is those that support campaigns of intimidation, threats and hatred that want to challenge it. It is those that want to use their speech to frighten and torment into submission others that dislike the enhanced punishments. It is those that want to enforce their views on society by force (which defines terrorism) that want it struck down.

We applaud Senator Feinstein for her stance in supporting legislation whose only goal is to respond to terrorist activities of a few and allow the rest of society to hold a civil debate on these the moral relationship between humans and non-human animals.

Regards,

David Jentsch and Dario Ringach